<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="220968">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00207025</url>
  </required_header>
  <id_info>
    <org_study_id>CA165-012</org_study_id>
    <nct_id>NCT00207025</nct_id>
  </id_info>
  <brief_title>A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies</brief_title>
  <official_title>A Phase I Study of BMS-275183 Given on a Daily Schedule in Patients With Advanced Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to learn about the safety and tolerability of
      daily BMS-275183 in patients with advanced cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK, preliminary evidence of antitumor activity</measure>
  </secondary_outcome>
  <enrollment>60</enrollment>
  <condition>Tumors</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-275183</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-hematologic malignancy that has progressed or no standard therapy is known

          -  Four weeks from last chemotherapy or two weeks from last non-cytotoxic therapy

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1

          -  No more than 3 prior chemotherapy regimens in advanced/metastatic setting

          -  Absolute neutrophil count &gt;=1,500/mm3 and platelets &gt;=100,000/mm3

          -  Bilirubin &lt;=1.5 x Upper Limit of Normal (ULN), Aspartate aminotransferase &lt;=2.5 x ULN

          -  Serum creatinine &lt;=1.5 x ULN

          -  Men and women &gt;=18 years

          -  Women of Child Bearing Potential (WOCBP) must use adequate method of contraception
             throughout and up to 4 weeks after the study

        Exclusion Criteria:

          -  WOCBP and men not using adequate method of birth control

          -  WOCBP who are pregnant or breastfeeding

          -  Prior radiation &gt;=25% of bone marrow containing skeleton

          -  Uncontrolled, significant, or active cardiovascular or pulmonary disease or infection
             or psychiatric disorder

          -  Neuropathy

          -  Active brain metastases

          -  Inability to swallow capsules

          -  History of gastrointestinal disease, surgery or malabsorption, or requiring use of a
             feeding tube

          -  Concurrent chemotherapy, hormonal therapy, immunotherapy, or radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trials Disclosure</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>July 2008</verification_date>
  <lastchanged_date>February 27, 2010</lastchanged_date>
  <firstreceived_date>September 12, 2005</firstreceived_date>
  <firstreceived_results_disposition_date>February 27, 2010</firstreceived_results_disposition_date>
  <keyword>Patients with advanced solid tumors</keyword>
  <!-- Results have not yet been posted, but a results disposition has been submitted -->
</clinical_study>
